Panel Discussion: Defining Clinical Endpoints & Exploring Surrogates for HBV Functional Cure
Time: 8:30 am
day: Day Two
Details:
• Reflecting cccDNA activity and assessing durability of hepatitis B surface antigen seroclearance
• Outlining parameters for acceptable and clinically meaningful hepatitis B surface antigen loss and opportunities to implement alternative surrogate endpoints
• Future directions: looking towards a sterilizing cure
